These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 3619468)

  • 1. [Enhancement of NK-activity and LAK-activity in combination therapy with interferon-alpha in a child with neuroblastoma].
    Fukushima K; Tanaka K; Matsumoto Y; Nishikawa K; Hoshika T; Kohno Y; Okada T; Shiraki K
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2597-9. PubMed ID: 3619468
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
    Edwards BS; Hawkins MJ; Borden EC
    Cancer Res; 1984 Jul; 44(7):3135-9. PubMed ID: 6586292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
    Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
    Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basic and interferon-augmented natural killer (NK) cell activity in psoriasis.
    Jansén CT; Viander M
    Acta Derm Venereol; 1983; 63(5):384-7. PubMed ID: 6197835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combined chemotherapy with alpha interferon for neuroblastoma].
    Sawada J; Itoi T; Ishii K; Tanaka T; Matsumura T
    Gan To Kagaku Ryoho; 1984 May; 11(5):1147-9. PubMed ID: 6721514
    [No Abstract]   [Full Text] [Related]  

  • 6. Cellular mechanisms of interleukin-12-mediated neuroblastoma regression.
    Redlinger RE; Shimizu T; Remy T; Alber S; Watkins SC; Barksdale EM
    J Pediatr Surg; 2003 Feb; 38(2):199-204. PubMed ID: 12596103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The significance and outlook of cytokines in cancer therapy].
    Nihon Gan Chiryo Gakkai Shi; 1988 Apr; 23(4):907-15. PubMed ID: 3144574
    [No Abstract]   [Full Text] [Related]  

  • 8. Interferon enhanced natural killer function in Hodgkin's disease.
    Levy S; Reins F; Aleksijevic A; Giron C; Oberling F; Mayer S; Lang JM
    Nouv Rev Fr Hematol (1978); 1986; 28(5):323-5. PubMed ID: 3808943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K; Varalakshmi C; Khar A
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.
    Zeng Y; Huebener N; Fest S; Weixler S; Schroeder U; Gaedicke G; Xiang R; Schramm A; Eggert A; Reisfeld RA; Lode HN
    Cancer Res; 2007 Mar; 67(5):2331-8. PubMed ID: 17332365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of natural killer cells in the mechanism of the antitumor effect of interferon on Moloney sarcoma virus-transformed cells.
    Fresa KL; Murasko DM
    Cancer Res; 1986 Jan; 46(1):81-8. PubMed ID: 3940213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Natural killer activity in brain tumor patients treated with interferon and steroid].
    Nakagawa Y; Ibayashi N; Ueda S; Hirakawa K; Amagai T; Imanishi J; Fukuma S
    Nihon Gan Chiryo Gakkai Shi; 1985 Dec; 20(10):2305-13. PubMed ID: 3831175
    [No Abstract]   [Full Text] [Related]  

  • 13. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon.
    Lotzová E; Savary CA; Quesada JR; Gutterman JU; Hersh EM
    J Natl Cancer Inst; 1983 Nov; 71(5):903-10. PubMed ID: 6580490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal recombinant alpha 2-interferon for 'salvage' immunotherapy in persistent epithelial ovarian cancer.
    Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD
    Cancer Treat Rev; 1985 Dec; 12 Suppl B():23-32. PubMed ID: 3833327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural killer activity of pediatric patients with acute lymphoblastic leukemia in remission.
    Inada M; Okawa H; Suzuki M; Yata J
    Jpn J Clin Oncol; 1984 Sep; 14(3):335-45. PubMed ID: 6592376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between in vitro and systemic effects of native and recombinant interferons-alpha on human natural killer cell cytotoxicity.
    Edwards BS; Hawkins MJ; Borden EC
    J Biol Response Mod; 1983; 2(5):409-17. PubMed ID: 6644345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of human natural killer cell cytotoxicity by recombinant leukocyte interferon clone A.
    Lotzová E; Savary CA; Gutterman JU; Quesada JR; Hersh EM
    J Biol Response Mod; 1983; 2(5):482-96. PubMed ID: 6644351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct suppression of natural killer activity in human peripheral blood leukocyte cultures by glucocorticoids and its modulation by interferon.
    Holbrook NJ; Cox WI; Horner HC
    Cancer Res; 1983 Sep; 43(9):4019-25. PubMed ID: 6871844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the natural killer cell-interferon system in patients with mid-gut carcinoid tumours treated with leucocyte interferon.
    Funa K; Alm GV; Rönnblom L; Oberg K
    Clin Exp Immunol; 1983 Sep; 53(3):716-24. PubMed ID: 6616963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of natural killer cell cytotoxicity in the peripheral blood of patients receiving interferon therapy.
    Spina CA; Fahey JL; Durkos-Smith D; Dorey F; Sarna G
    J Biol Response Mod; 1983; 2(5):458-69. PubMed ID: 6644350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.